Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry by Henderson, Lauren A. et al.
Medication use in juvenile uveitis patients
enrolled in the Childhood Arthritis and
Rheumatology Research Alliance Registry
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Henderson, Lauren A., David Zurakowski, Sheila T. Angeles-
Han, Andrew Lasky, C. Egla Rabinovich, and Mindy S. Lo. 2016.
“Medication use in juvenile uveitis patients enrolled in the
Childhood Arthritis and Rheumatology Research Alliance Registry.”
Pediatric Rheumatology Online Journal 14 (1): 9. doi:10.1186/
s12969-016-0069-5. http://dx.doi.org/10.1186/s12969-016-0069-5.
Published Version doi:10.1186/s12969-016-0069-5
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:25658377
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH ARTICLE Open Access
Medication use in juvenile uveitis patients
enrolled in the Childhood Arthritis and
Rheumatology Research Alliance Registry
Lauren A. Henderson1*, David Zurakowski2, Sheila T. Angeles-Han3, Andrew Lasky4, C. Egla Rabinovich5,
Mindy S. Lo1 and for the CARRA Registry Investigators
Abstract
Background: There is not yet a commonly accepted, standardized approach in the treatment of juvenile idiopathic
uveitis when initial steroid therapy is insufficient. We sought to assess current practice patterns within a large cohort of
children with juvenile uveitis.
Methods: This is a cross-sectional cohort study of patients with uveitis enrolled in the Childhood Arthritis and
Rheumatology Research Alliance (CARRAnet) registry. Clinical information including, demographic information,
presenting features, disease complications, and medications were collected. Chi-square and Fisher’s exact tests
were used to assess for associations between medications and clinical characteristics.
Results: Ninety-two children with idiopathic and 656 with juvenile idiopathic arthritis (JIA)-associated uveitis
were identified. Indication (arthritis or uveitis) for medication use was not available for JIA patients; therefore,
detailed analysis was limited to children with idiopathic uveitis. In this group, 94 % had received systemic
steroids. Methotrexate (MTX) was used in 76 % of patients, with oral and subcutaneous forms given at similar
rates. In multivariable analysis, non-Caucasians were more likely to be treated initially with subcutaneous MTX
(P = 0.003). Of the 53 % of patients treated with a biologic DMARD, all received a tumor necrosis factor (TNF)
inhibitor. TNF inhibitor use was associated with a higher frequency of cataracts (52 % vs 21 %; P = 0.001) and
antinuclear antibody positivity (49 % vs 29 %; P = 0.04), although overall complication rates were not higher in
these patients.
Conclusion: Among idiopathic uveitis patients enrolled in the CARRAnet registry, MTX was the most commonly used
DMARD, with subcutaneous and oral forms equally favored. Patients who received a TNF inhibitor were more likely to
be ANA positive and have cataracts.
Keywords: Uveitis, Juvenile idiopathic arthritis (JIA), Idiopathic uveitis, DMARD, Infliximab, Adalimumab, Methotrexate
Background
Non-infectious juvenile uveitis is an inflammatory
ocular disease that can lead to visual disability if not
adequately controlled. Uveitis occurs as a primary disease
(idiopathic uveitis) but can also be associated with sys-
temic disease, typically juvenile idiopathic arthritis (JIA).
In the pediatric population, uveitis remains a diagnostic
challenge because children may not report symptoms
until substantial visual damage has accrued. Rapid
and effective control of the disease is essential because
prolonged ocular inflammation is associated with higher
rates of ocular complications and vision loss [1–3]. Unfor-
tunately, there is no uniform approach to the evaluation
and treatment of juvenile uveitis. In part, the lack of
standardization is due to the limited number of clinical
studies in this condition. Current treatment strategies for
juvenile uveitis are mostly extrapolated from small, retro-
spective case series and there have been no randomized
controlled trials in this patient population. In addition,
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few studies have examined treatment practice patterns in
the care of juvenile uveitis, and these patterns may also
vary between pediatric rheumatology and ophthalmology
providers. Improved understanding of current practice
may help inform future decisions regarding optimal care
of these patients.
Glucocorticoids (oral and/or topical) are often the
first step in treatment of anterior, non-infectious uve-
itis in children but long term use is discouraged due
to side effects [4, 5]. Methotrexate is the most com-
monly prescribed steroid-sparing medication, and its
therapeutic efficacy has been documented in several
small case series [4, 6–10]. Methotrexate can be given
either orally or subcutaneously. Subcutaneous admin-
istration has greater bioavailability compared to oral,
which can be quite variable [11, 12]. However, for many
patients, especially children, oral dosing is preferred.
Other disease-modifying anti-rheumatic drugs (DMARDs)
such as cyclosporine, tacrolimus, azathioprine, and my-
cophenolate mofetil are also used to treat uveitis, al-
though most published reports have focused on adult,
rather than pediatric, patients [13–23]. More recently,
reports describe successful use of the TNF inhibitors
infliximab and adalimumab in both JIA-associated and
idiopathic uveitis [24–27]. In refractory cases of JIA as-
sociated uveitis, tociluzumab, abatacept, and rituximab
have also been used [28–30].
Several groups have proposed guidelines for the
treatment of JIA-associated uveitis based on literature
review and expert opinion [31–33]. There is consen-
sus among these treatment guidelines that topical ste-
roids should be used first, followed by methotrexate
for refractory disease. However, they differ in their
recommendations on the use of systemic glucocorti-
coids, preferred route of methotrexate administration,
and choice of second-line steroids sparing agents.
Further, they have not yet been validated prospectively
and it is unknown how closely providers adhere to
these recommendations.
Comparative effectiveness research (CER) represents
an alternative approach to the establishment of treat-
ment guidelines by expert opinion. CER methodologies
are well suited to study diseases such as juvenile uveitis
that are relatively uncommon, making randomized con-
trolled trials with large cohorts less feasible [34, 35].
Consensus Treatment Plans (CTPs), in which patients
are treated according to one of several algorithms, are
intended to help standardize care, while at the same
time collecting information on outcomes that will allow
comparison of different treatment practices. The imple-
mentation of CTPs and subsequent analysis of outcome
data represent a form of CER. This approach has been
trialed for multiple pediatric rheumatologic conditions,
though not juvenile uveitis [36–39].
In this study, we examined data from CARRAnet, a
large registry of North American pediatric rheumatol-
ogy patients, in order to characterize current practice
patterns in the treatment of juvenile uveitis. Better
understanding of the factors influencing selection of
steroid-sparing medications is necessary to inform the
development of standardized treatment regimens and
CTPs.
Methods
CARRAnet registry
CARRAnet was developed by the Childhood Arthritis
and Rheumatology Research Alliance (CARRA) and is a
multicenter registry of children with rare pediatric rheu-
matologic conditions (“CARRA registry” on https://clini-
caltrials.gov). Over 50 pediatric rheumatology research
centers in the United States and Canada have enrolled
over 9000 children into the registry since its inception.
Children were eligible to participate if they had 1 of 12
specified rheumatologic diseases that were being studied
in the registry. The primary diagnosis at enrollment was
determined by the child’s treating rheumatologist. The
registry opened with recruitment of children with JIA in
May 2010; recruitment of children idiopathic uveitis
began in February 2012, at which time collection of de-
tailed information on uveitis presentation and treatment
was also introduced to the registry. Demographic and
clinical data, including information on prior medication
use and disease complications, were gathered by family
interview, medical record review, and/or provider recall
and subsequently entered into a secure online database.
Consent/assent was obtained from all study participants.
Uveitis data
After Institutional Review Board approval, we obtained
de-identified enrollment data from children with JIA-
associated and idiopathic uveitis who participated in the
CARRA registry from June 2010 to September 2013. Al-
though the registry was developed for prospective data
collection, at the time of our inquiry, only data from a
single, baseline registry enrollment visit was available for
most patients. Data collected included uveitis type,
number of affected eyes,duration of current episode (if
active uveitis present), history of ocular complications,
and current and prior medication use. Possible ocular
complications listed included increased intraocular
pressure, keratic precipitates, posterior synechiae, cata-
racts, macular edema, epiretinal membrane, snowbanks,
snowballs, retinal vasculitis, macular atrophy, hypopyon,
iris nodules, band keratopathy, and history of eye surgery.
Information on topical therapies (steroid, mydriatic,
and anti-glaucoma drops), systemic glucocorticoids,
intra-ocular steroids, intravenous immunoglobulin,
non-biologic disease-modifying antirheumatic drugs
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(DMARDs), and biologic agents were included in the
registry. Long-term steroid use was defined as a history of
systemic glucocorticoid treatment for > 1 month. Drug
use was categorized as “current,” “past,” “never,” or “un-
known.” For this analysis, “ever drug use” was defined as
past and/or current use. Information on medication dose
and dates of drug initiation/cessation were not included in
the registry. Thus, while some longitudinal information
regarding treatment could be inferred based on current
and past use of medications, details such as duration of
therapy were not available. For JIA patients, the indication
for a systemic medication (arthritis vs. uveitis) was not re-
corded. Finally, data collection also included “ANA sta-
tus,” where a positive response was defined as a history of
testing positive for anti-nuclear antibody (ANA). Date of
ANA testing was not included in the registry.
Statistical analysis
Demographic differences between JIA-associated and
idiopathic uveitis groups were compared with Mann-
Whitney U and chi-square tests. Univariate analysis
was performed between first-use of oral MTX and
subcutaneous MTX, and between biologic and non-
biologic groups, using the Mann-Whitney U-test for
median age and Fisher’s exact test for percentages.
Multivariable logistic regression (backward selection)
was applied to identify predictive factors, with the
likelihood ratio test used to assess significance of the
independent predictors [40]. Odds ratios and 95 %
confidence intervals (CI) were derived for significant
multivariable predictors of route of MTX administra-
tion and for use of biologics.
In these univariate and multivariate analyses, Caucasian
race included both Hispanic and non-Hispanic ethnicities.
Due to the small number of subjects endorsing racial
categories other than Caucasian/white and black/African
American, racial categories were collapsed into Caucasian
and non-Caucasian to allow sufficient patient num-
bers for statistical analysis. Statistical analysis was per-
formed using IBM/SPSS Statistics (version 22.0, IBM,
Armonk, NY). Two-tailed P < 0.05 were considered
statistically significant.
Results
Patient characteristics
There were 92 children with idiopathic uveitis and
646 children with JIA uveitis identified in the CARRA
registry (Table 1). Children with JIA uveitis were signifi-
cantly younger at disease onset (median age 2.8 years)
than children with idiopathic uveitis (median 8.5 years)
(P < 0.001) (Table 1). Females were more frequently
affected than males in both forms of the disease;
however, patients with JIA uveitis were more likely to
be female than those with idiopathic uveitis (78 % vs
55 %; P < 0.001) (Table 1). A greater percentage of patients
with JIA uveitis (92 %) were Caucasian as compared to
children with idiopathic uveitis (77 %) (P < 0.001) (Table 1).
Uveitis characteristics
Information on uveitis disease characteristics and ocu-
lar complications was available for all patients with
idiopathic uveitis but only 69 of 646 patients with JIA
uveitis. Therefore, our evaluation of uveitis features
was limited to patients with idiopathic uveitis. Anterior
uveitis was the most common subtype of the disease
(62 %), followed by panuveitis (21 %), intermediate uveitis
(13 %), and posterior uveitis (4 %). Most children with
idiopathic uveitis (77 %) had bilateral involvement. Ocular
complications were common and noted in 71 (77 %) chil-
dren with idiopathic uveitis: 35 had cataracts, 26 had
undergone eye surgery, 13 had abnormal corrected vision,
and 3 were blind in the affected eye (Fig. 1). Other fre-
quently reported complications included posterior syne-
chiae, band keratopathy, macular edema, and keratic
precipitates. The majority of patients (64 children) re-
ported having more than one complication. Among JIA
uveitis patients for whom ocular complication data was
Table 1 Subject characteristics
Idiopathic Uveitis JIA Uveitis
N = 92 N = 646
Age at onset, yrs 8.5 2.8
Median (IQR) (5.3-10.9) (1.7-5.2)
Gender (n, %)
Female 51 (55 %) 504 (78 %)
Male 41 (45 %) 142 (22 %)
Disease duration, yrs
Median (IQR) 2.9 (1.2-5.2) 6.1 (3.2-9.5)
Race* (n, %)
Caucasian 71 (77 %) 596 (92 %)
Black 12 (13 %) 22 (3 %)
Asian 4 (1 %) 16 (2 %)
Other 3 (3 %) 19 (3 %)
Unknown 2 (2 %) 0 (0 %)
Ethnicity (n, %)
Hispanic 12 (13 %) 61 (9 %)
Non-Hispanic 79 (86 %) 580 (90 %)
Unknown 1 (1 %) 5 (0.5 %)
ANA (n, %)
Positive 30 (32 %) 385 (60 %)
Negative 45 (49 %) 184 (28 %)
Unknown 17 (18 %) 77 (12 %)
Characteristics of the idiopathic and JIA uveitis patients are listed in the table.
*Race was self-reported, and subjects could select more than one category
JIA juvenile idiopathic arthritis, IQR interquartile range
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known, cataracts again were the most common com-
plication, although overall complication rate was
lower (Additional file 1: Figure S1).
Medication use
Data on medications ever used was available on all
idiopathic and almost all (643/646) JIA uveitis patients
(Tables 2 and 3). Use of DMARDs and biologic agents
was similar in both groups. A majority of patients re-
ceived a DMARD (83 % of idiopathic and 88 % of JIA
uveitis patients). At least one biologic agent was used in
53 % of children with idiopathic uveitis and 56 % of chil-
dren with JIA-associated uveitis. In patients with JIA
uveitis, the indication for medication use was not specified
and could have been due to either arthritis or uveitis dis-
ease activity. Therefore, in order to evaluate medication
use for uveitis specifically, we restricted the remaining
medication analysis to patients with idiopathic disease.
Glucocorticoid use in idiopathic uveitis
Topical steroid drops were used in 90 % of idiopathic
uveitis patients, with hourly dosing employed at some
point in the disease course in 26 % (Table 4). Of the 5
children who did not receive topical steroid drops, 4
were treated with oral or IV glucocorticoids. None of the
idiopathic uveitis patients received intra-ocular steroid
injections. Almost all (94 %) of idiopathic uveitis patients
had received systemic glucocorticoids. Further, 38 % of
idiopathic uveitis patients had received long-term sys-
temic glucocorticoids.
DMARD use in idiopathic uveitis
Of the 92 idiopathic uveitis patients, 70 (76 %) received
methotrexate (MTX), making it the most frequently uti-
lized steroid-sparing agent. Overall, the oral and sub-
cutaneous (SQ) forms of MTX were used at similar rates
(Table 2). In 96 % of patients who had received MTX, it
was possible to determine the initial route of MTX ad-
ministration prescribed to treat idiopathic uveitis. SQ
MTX was used first in 54 % of children, while oral MTX
was prescribed first in 46 %. A minority (29 %) of pa-
tients had been trialed on both formulations (SQ to oral
in 10 patients; oral to SQ in 7 patients; in 3 subjects the
order could not be determined). By univariate analysis,
Fig. 1 Ocular Complications in Idiopathic Uveitis. The number of
idiopathic uveitis patients with each ocular complication is depicted
in the figure
Table 2 DMARD use in idiopathic and JIA uveitis
Drug Idiopathic Uveitis JIA Uveitis
N = 92 (%) N = 643 (%)
Methotrexate 70 (76) 549 (85)
Oral 44 (48) 375 (58)
SQ 46 (50) 416 (65)
Mycophenolate mofetil 9 (10) 33 (5)
Cyclosporine 3 (3) 20 (3)
Sulfasalazine 1 (1) 47 (7)
Hydroxychloroquine 0 (0) 27 (4)
Leflunomide 0 (0) 20 (3)
Tacrolimus 0 (0) 8 (1)
Azathioprine 0 (0) 3 (0.4)
Cyclophosphamide 0 (0) 1 (0.2)
Data in this table represent “ever drug use” in patients with data available on
DMARD drug exposure (92/92 patients with idiopathic uveitis and 643/646
patients with JIA uveitis)
JIA juvenile idiopathic arthritis, SQ subcutaneous
Table 3 Biologic agent use in idiopathic and JIA uveitis
Drug Idiopathic Uveitis JIA Uveitis
N = 92 (%) N = 643 (%)
TNF inhibitor 49 (53) 353 (55)
Adalimumab 18 (20) 196 (30)
Certolizumab 0 (0) 1 (0.2)
Etanercept 0 (0) 159 (25)
Golimumab 1 (1) 3 (0.5)
Infliximab 36 (39) 174 (27)
Abatacept 0 (0) 23 (4)
Anti-IL-1 0 (0) 9 (1.5)
Anakinra 0 (0) 7 (0.2)
Rilonacept 0 (0) 1 (0.2)
Canakinumab 0 (0) 1 (0.2)
Rituximab 0 (0) 4 (0.5)
Tocilizumab 0 (0) 4 (0.5)
Data in this table represent “ever drug use” in patients with data available on
biologic drug exposure (92/92 patients with idiopathic uveitis and 643/646
patients with JIA uveitis)
JIA juvenile idiopathic arthritis
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the initial use of the SQ MTX was associated only
with non-Caucasian race (P = 0.046). This relationship
persisted in the multivariable analysis with adjustment
for age at disease onset, ethnicity, race, gender, uveitis
type, and ocular complications (P = 0.003) (Table 5).
DMARDs other than methotrexate that were less fre-
quently used in idiopathic uveitis patients included
cyclosporine (N = 3), mycophenolate mofetil (N = 9),
and sulfasalazine (N = 1) (Table 2).
Biologic use in idiopathic uveitis
Among the 49 idiopathic uveitis patients treated with a
biologic medication, all received a tumor necrosis factor
(TNF) inhibitor: infliximab (n = 36), adalimumab (n = 18),
or golimumab (n = 1) (Table 3). Of these, all but 2 had also
received methotrexate. In univariate analysis, patients
who had received a TNF inhibitor were more likely to
have a history of a cataract compared to patients who
had never been exposed to a biologic agent (53 % vs.
21 %; P = 0.002) (Table 6). This association remained
in multivariable analysis adjusting for age at disease
onset, ethnicity, race, gender, uveitis type, ANA status,
and ocular complications (odds ratio = 5.6; P = 0.001). In
addition, multivariate modeling also revealed that a
positive ANA, defined as a history of testing positive
for ANA, was significantly associated with TNF in-
hibitor use after adjusting for other disease and pa-
tient characteristics (P = 0.04) (Table 6).
Multiple biologic agent use in idiopathic uveitis
Six idiopathic uveitis patients were treated with multiple
biologic agents. All of these patients had received both
infliximab and adalimumab. In 5 of these patients, the
order of TNF inhibitor use could be determined: 3 pa-
tients switched from adalimumab to infliximab, while 2
patients switched from infliximab to adalimumab.
Biologic use without preceding DMARD in idiopathic uveitis
Two patients included in the registry were treated with
infliximab without a preceding DMARD. Neither of
these patients had anterior uveitis, while both had ocular
complications. The first patient was diagnosed with bi-
lateral panuveitis and had developed snowballs and pos-
terior synechiae. The second child had posterior uveitis
complicated by retinal vasculitis and blindness in the af-
fected eye.
Discussion
Optimization of care for children with uveitis remains a
challenging goal without better comparative effectiveness
studies. These types of studies are particularly challen-
ging to conduct in children given the rarity of uveitis
and the practical considerations regarding therapeutic
trials in children. In this study, we sought to present a
preliminary overview of current practice patterns in the
treatment of pediatric uveitis, using a large North
American patient registry. This analysis includes descrip-
tion of one of the largest cohorts of pediatric idiopathic
uveitis patients published to date. A total of 26 contrib-
uting centers were represented within this cohort.
We first examined steroid use in these patients.
Somewhat surprisingly, nearly all patients had been
treated with systemic glucocorticoids; indeed, more
patients reported using systemic glucocorticoids than
topical steroids. About a third of patients reported
long-term use of systemic glucocorticoids, and several
patients had received intravenous glucocorticoid
pulses. In contrast to the pattern of steroid use docu-
mented in our cohort of patients, published treatment
Table 4 Steroid use in idiopathic uveitis
Idiopathic Uveitis N (%)
Topical steroid drops
Yes 83 (90)
No 5 (5)
Unknown 4 (4)
Max topical steroid drop freq
Hourly 24 (26)
12x/day 10 (11)
6x/day 4 (4)
4x/day 16 (17)
3x/day 6 (7)
2x/day 3 (3)
Daily 3 (3)
Unknown 21 (23)
Intraocular steroids
Yes 0 (0)
No 85 (92)
Unknown 7 (8)
Systemic steroids
Yes 86 (94)
No 4 (4)
Unknown 2 (2)
IV pulse steroids
Yes 4 (4)
No 82 (89)
Unknown 6 (7)
Long-term systemic steroids
Yes 35 (38)
No 50 (54)
Unknown 7 (8)
Topical and systemic steroid use in idiopathic uveitis patients is depicted in
the table. Max maximum, freq frequency
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guidelines for JIA-associated uveitis reserve systemic
glucocorticoids for patients with severe ocular inflam-
mation (grades 3+ or 4+) or impending vision loss
[31, 32]. The discrepancy between systemic glucocortic-
oid use in our cohort compared to the treatment guide-
lines may represent a point where current treatment
practices deviate from expert opinion. It is possible that
this deviation is due to differences in treatment ap-
proaches between idiopathic and JIA-associated uveitis.
Alternatively, the high rate of systemic glucocorticoiduse
in our cohort could be explained by higher disease sever-
ity, a possibility that is difficult to assess as the CARRAnet
registry did not include information about grade of in-
flammation. However, the overall rate of ocular compli-
cations in our cohort (80 %) is within the range of
prior reports in juvenile uveitis [1, 2, 41].
The use of steroid-sparing medications in idiopathic
uveitis was then evaluated. Most patients had received
methotrexate, in either oral or subcutaneous form. Sub-
cutaneous methotrexate has higher bioavailability than
oral dosing, but use of subcutaneous methotrexate for
initial therapy is not clearly standard among providers.
We found that idiopathic uveitis patients in our study
were evenly divided between oral and subcutaneous
dosing. Univariate and multivariate analysis demon-
strated that subcutaneous administration was used
more frequently for non-Caucasians than Caucasians.
A possible explanation could be that non-Caucasians
had, or were at least perceived to have, more severe
disease. However, other characteristics such as com-
plication rate, age of onset, gender, and ANA status
were not different between patients who were treated
with oral versus subcutaneous methotrexate. There is
limited literature on the role of race and ethnicity in
juvenile uveitis. In one study of JIA-associated uveitis,
African-American children tended to have worse phys-
ician global assessment scores [42]. Another study has also
suggested that African-American patients may have more
severe disease [43]. In contrast, white race was a predictor
of remission in one study of JIA-associated uveitis, but
race was not a factor affecting development of complica-
tions [44]. Whether these findings are applicable to
idiopathic uveitis patients is less clear. Other factors
that may influence medication selection were not able
Table 5 Factors associated with initial route of MTX Administration in idiopathic uveitis
Multivariable Logistic Regression
Variable Oral MTX SQ MTX Univariate
P value
Odds Ratio 95 % CI P value
N = 31 N = 36
Age at onset, yrs 0.06 0.61
Median (IQR) 9.4 (5.7-11.8) 7.1 (5.0-9.3)
Gender 1.00 0.73
Female 13 (42 %) 15 (42 %)
Male 18 (58 %) 21 (58 %)
Ethnicity 1.00 0.72
Hispanic 2 (6 %) 2 (6 %)
Non-Hispanic 29 (94 %) 34 (94 %)
Race 0.046* 12.7 1.5-106.8 0.003*
Caucasian 27 (87 %) 22 (65 %)
Non-Caucasian 4 (13 %) 12 (35 %)
Uveitis type 0.65 0.51
Anterior 19 (61 %) 26 (72 %)
Pan 4 (13 %) 5 (14 %)
Intermediate 7 (23 %) 4 (11 %)
Posterior 1 (3 %) 1 (3 %)
ANA status 1.00 0.95
Positive 11 (44 %) 15 (44 %)
Negative 14 (56 %) 19 (56 %)
Complications** 25 (81 %) 28 (80 %) 1.00 0.73
Cataracts 15 (48 %) 16 (44 %) 0.81 0.94
Data in this table include subject characteristics associated with the route of methotrexate administration initially prescribed
IQR interquartile range, SQ subcutaneous, CI confidence interval, ANA antinuclear antibody
*Statistically significant, **Presence of at least one ocular complication
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to be captured in our study; these include patient prefer-
ence, concerns about medication compliance, and regional
availability of injectable methotrexate due to drug short-
ages [45].
More than half of our idiopathic uveitis cohort received
biologic therapy, all in the form of TNF inhibitors. Inflixi-
mab was used twice as frequently as adalimumab, which
was interesting given that recent literature seems to have
favored adalimumab over infliximab in some analyses
[46, 47]. One explanation for this may be the earlier
availability of infliximab. However, our patients were
first enrolled beginning in 2010; adalimumab use in
juvenile uveitis was reported as early as 2006 [48].
There were no racial differences between patients
who had or had not received TNF inhibitor therapy.
However, patients treated with TNF inhibitors were
more likely to be ANA positive and to have cata-
racts, again suggesting that these patients either had,
or were perceived to have, more severe disease. Un-
fortunately, the design of the registry did not allow
the ability to capture whether ANA positivity and
cataract development preceded or followed TNF inhibitor
administration. Several studies have identified ANA posi-
tivity as a risk factor for ocular complications and visual
acuity loss in JIA-associated uveitis; however, other studies
have not replicated this finding [2, 49–51]. There is, thus,
no clear explanation of the association between ANA
positivity and TNF inhibitor use in our cohort apart from
the possible perception of increased disease severity.
Cataract development may be secondary to disease ac-
tivity or chronic steroid use. In our cohort, patients with
cataracts had higher frequencies of other ocular compli-
cations but similar rates of glucocorticoiduse compared
to children without cataracts. Thus, differences in dis-
ease severity more likely explain the association between
cataract development and the use of TNF inhibitors.
Further understanding of this relationship is limited by
the available data, which in this registry database did not
specify the timing of TNF inhibitor initiation with regard
to cataract formation.
Limitations
Although the size of our idiopathic uveitis pediatric co-
hort was relatively large, interpretation of the impact of
Table 6 Factors associated with biologic agent use in idiopathic uveitis
Multivariable Logistic Regression
Variable Biologics No Biologics Univariate
P value
Odds Ratio 95 % CI P value
N = 49 N = 43
Age at onset, yrs 0.35 0.90
Median (IQR) 7.7 (5.1-10.2) 8.9 (6.8-11.4)
Gender 0.21 0.07
Female 24 (49 %) 27 (63 %)
Male 25 (51 %) 16 (37 %)
Ethnicity 0.54 0.92
Hispanic 5 (10 %) 7 (16 %)
Non-Hispanic 44 (90 %) 36 (84 %)
Race 0.20 0.87
Caucasian 35 (73 %) 36 (86 %)
Non-Caucasian 13 (27 %) 6 (14 %)
Uveitis type 0.44 0.82
Anterior 27 (55 %) 30 (70 %)
Pan 13 (27 %) 6 (14 %)
Intermediate 7 (14 %) 5 (12 %)
Posterior 2 (4 %) 2 (5 %)
ANA status 0.07***
Positive 20 (49 %) 10 (29 %) 3.0 1.0-8.6 0.04*
Negative 21 (51 %) 25 (71 %) Reference
Any complication 39 (81 %) 32 (74 %) 0.46 0.16
Cataracts 26 (53 %) 9 (21 %) 0.002* 5.6 1.8-17.2 0.001*
IQR interquartile range, CI confidence interval
*Statistically significant, ***Trend
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specific medications on patient outcome is limited by
the lack of follow up. This was a relatively early cross-
sectional look at enrollment data, but collection of data
from follow up visits remains ongoing. We hope that
over time, further analyses will allow more detailed
examination of the factors that influence the selection of
medications, as well as their efficacy.
The CARRAnet database did not include data on the
indication for medication use in JIA uveitis patients.
Therefore, it was not possible to determine if a medica-
tion was used for active arthritis and/or uveitis. Thus,
we limited the majority of our analysis to idiopathic uve-
itis patients. It is unclear if our findings are applicable to
JIA uveitis patients, given the differences in race, gender,
and ANA status in both groups which may be associated
with differences in disease severity, and subsequently
medication use. The database also did not collect infor-
mation on medication dosage, which can also vary
greatly from provider to provider and also influence the
decision for whether to move on to another agent. Fu-
ture iterations of this database will hopefully allow more
granular analysis of medication dosage.
Finally, our cohort may be influenced by selection bias,
as these patients were all under the care of a pediatric
rheumatologist. Patients with milder disease may be
managed solely by ophthalmologists without coming to
the attention of a rheumatology provider.
Conclusions
There is not yet a commonly accepted, standardized ap-
proach in the treatment of juvenile idiopathic uveitis.
Analysis of a North American pediatric rheumatology
data registry identified points of consensus and diver-
gence in the current treatment practices for this disease.
Compared to expert treatment guidelines, clinicians used
systemic steroids more frequently and for prolonged
courses. Steroid-sparing treatment strategies were gener-
ally similar for children with JIA-associated and idio-
pathic uveitis. Among patients with idiopathic uveitis,
almost all were treated with methotrexate, although oral
and subcutaneous forms of the medication were equally
favored. Non-Caucasian patients were more likely to be
prescribed subcutaneous rather than oral methotrexate.
More than half of our idiopathic uveitis patients were
also treated with a TNF inhibitor, and infliximab was
used twice as often as adalimumab. TNF inhibitor use
may reflect higher disease severity, or the perception of
higher disease activity, as it was also associated with
higher rates of ANA positivity and cataract formation.
Our findings on the treatment of juvenile uveitis in
North America lay the foundation for future investigation
into identified areas of treatment variability. Comparative
effectiveness research, particularly CTPs, will be helpful in
studying systemic steroid use and the efficiency of oral
versus subcutaneous methotrexate, and the TNF inhibi-
tors infliximab and adalimumab.
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